Experience with rituximab in rheumatoid arthritis

Indian Journal of Rheumatology

Volumn 4, Issue 3, 2009, Pages 136-137

  Narayanan, K ^a   Bhakuni, D S ^a   Garg, O P ^a  

^a ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; RITUXIMAB;

CLINICAL TRIAL; DISEASE DURATION; HUMAN; LETTER; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84992229213     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(10)60197-5     Document Type: Letter

References (9)

1. th ed. Washington DC: ASM Press 2001; p 101.
2. Cohen SB, Emery P, Maria WG, Dougados M, Furie RA, Genovese MC, et al for the REFLEX trial group. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006; 54: 2793-2806
3. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 41: 315-324
4. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in RA. Arthritis Rheum 1995; 38: 727-735
5. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the EULAR response criteria for RA. Comparison with the preliminary ACR and WHO/ILAR criteria. Arthritis Rheum 1996; 39: 34-40.
6. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 2007; 56: 3896-3908
7. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity- guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responded. Arthritis Rheum 2008; 58: 3657-64.
8. Popa C, Leandron MJ, Cambrige G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology 2007; 46: 626-630 (Pubitemid 46523308)
9. McGonagle D, Tan AL, Madden J, Taylor L, Emery P. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD resistant rheumatoid arthritis. Rheumatology 2008; 47: 865-867 (Pubitemid 351796374)